Engineers at the Massachusetts Institute of Technology (MIT) have developed a tiny device that can be implanted under the skin to deal with the hypoglycemia crisis in patients with type 1 diabetes. The device automatically releases glucagon when blood sugar drops to dangerous levels, preventing life-threatening conditions.
Hypoglycemia is a common risk for people with type 1 diabetes and can lead to confusion, seizures, and even death. Traditional treatment relies on patients to self-inject glucagon, but it is often difficult for patients at night or in children to detect symptoms and respond promptly. The device designed by the MIT team is about the size of a coin and uses 3D printed polymer reservoirs and shape memory alloy sealing technology. When the body temperature is heated to 40 degrees Celsius, the alloy deforms and releases the drug.
The device supports wireless triggering and can be linked with a blood glucose monitor to achieve fully automatic emergency response. In animal experiments, the device implanted into diabetic mice stabilized blood sugar levels within 10 minutes. The study also verified the potential of this technology for epinephrine delivery, providing new ideas for first aid for heart disease or allergies.
The current device implantation time is up to 4 weeks, and the team plans to extend it to more than 1 year. Although the implant may be surrounded by fibrous tissue, the drug release function is not affected. The next step will be to advance animal experiments and plan to launch clinical trials within three years.
This breakthrough not only provides diabetic patients with more reliable protection against hypoglycemia, but may also revolutionize the delivery of emergency medications. The research results have been published in the journal Nature Biomedical Engineering.